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Introduction
Glucose-stimulated insulin release displays a biphasic pattern 
in both in vitro and in vivo systems (Curry et al., 1968; Rorsman 
et al., 2000). This pattern consists of a rapidly initiated and tran-
sient fi  rst phase preceding a sustained second phase. The ability 
of glucose to evoke fi  rst-phase release is shared by other stimuli 
(such as high KCl stimulation), resulting in membrane depolar-
ization followed by increased cytosolic Ca
2+, whereas only fuel 
secretagogues are able to initiate second-phase insulin release 
(Henquin, 2000). Electrophysiological experiments in single β 
cells have shown that fi  rst-phase release refl  ects Ca
2+- dependent 
exocytosis of primed granules in a readily releasable pool 
of granules, whereas second-phase release involves an ATP-
dependent release of granules that may be located further from 
the release site in a reserve pool (Rorsman et al., 2000; Rorsman 
and Renstrom, 2003). These results suggest that the two phases 
of release subject insulin granules to nonsynonymous regula-
tory mechanisms.
Fundamental components of secretory machinery, such as 
SNARE, required for the docking and fusion of vesicles in neu-
ronal cells (Südhof, 2004), are expressed in pancreatic β cells 
and play an important role in insulin exocytosis (Nagamatsu 
et al., 1996; Wheeler et al., 1996; Nagamatsu et al., 1999). 
Although the function of SNAREs in docking and fusion during 
exocytosis is already established (Jahn et al., 2003; Südhof, 
2004), the distinct role of SNAREs in the individual phases of 
insulin release remains unclear.
Interestingly, the expression of t-SNARE, syntaxin 1A/
HPC-1 (Synt1A; Bennett et al., 1992; Inoue et al., 1992), and its 
cognate SNARE partners, synaptosome-associated protein of 
25 kD (SNAP-25) and vesicle-associated membrane protein 2 
(VAMP2), reportedly decreased in islets of the Goto-Kakizaki 
rat, an animal model for human type 2 diabetes (Nagamatsu 
et al., 1999; Gaisano et al., 2002; Zhang et al., 2002), and in 
type 2 diabetic patients (Ostenson et al., 2006). Because type 2 
diabetes is associated with disturbances in the release pattern 
manifested as the selective loss of fi  rst-phase release (Ward et al., 
1984; O’Rahilly et al., 1986; Cerasi, 1994), SNAREs may have 
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T
he mechanism of glucose-induced biphasic insulin 
release is unknown. We used total internal reﬂ  ection 
ﬂ   uorescence (TIRF) imaging analysis to reveal the 
process of ﬁ   rst- and second-phase insulin exocytosis in 
pancreatic  β cells. This analysis showed that previously 
docked insulin granules fused at the site of syntaxin (Synt)1A 
clusters during the ﬁ   rst phase; however, the newcomers 
fused during the second phase external to the Synt1A clus-
ters. To reveal the function of Synt1A in phasic insulin exo-
cytosis, we generated Synt1A-knockout (Synt1A
−/−) mice. 
Synt1A
−/− β cells showed fewer previously docked gran-
ules with no fusion during the ﬁ  rst phase; second-phase 
  fusion from newcomers was preserved. Rescue experiments 
restoring Synt1A expression demonstrated restoration of 
granule docking status and fusion events. Inhibition of other 
syntaxins, Synt3 and Synt4, did not affect second-phase 
insulin exocytosis. We conclude that the ﬁ   rst phase is 
Synt1A dependent but the second phase is not. This indi-
cates that the two phases of insulin exocytosis differ spa-
tially and mechanistically.
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a specialized role in phasic insulin exocytosis. In the present 
study, we used Synt1A
−/− mice and total internal refl  ection 
fl  uorescence (TIRF) imaging to investigate a potential role 
for Synt1A in fi  rst-phase insulin release. Synt1A
−/− pancreatic 
β cells displayed no fusion from previously docked granules in 
fi  rst-phase release, whereas fusion from newcomers, which are 
responsible for second-phase release, was still preserved. Thus, 
we propose a new model for biphasic insulin release wherein 
docking and fusion of insulin granules is Synt1A dependent 
during the fi  rst phase but Synt1A independent during the sec-
ond phase.
Results
Interaction between insulin granules 
and Synt1A during biphasic insulin release
We initially analyzed the dynamic interaction between insulin 
granules and Synt1A in control mouse β cells using dual-color 
TIRF microscopy (TIRFM). Expression of GFP-tagged insulin 
allowed insulin granule observation, and Synt1A was detected 
by a TAT-conjugated Cy3-tagged mAb. Here, we chose not to use 
a conventional overexpression approach, such as Synt1A tagged 
with GFP or RFP, because overexpression of syntaxin disturbs 
the function of endogenous syntaxin molecules (Nagamatsu 
et al., 1996). Therefore, to analyze the interaction between 
insulin granules and Synt1A clusters during biphasic insulin 
  release, we labeled the endogenous Synt1A clusters with TAT 
antibody. As previously reported (Ohara-Imaizumi et al., 2004a), 
TAT-conjugated Cy3-labeled anti-Synt1A antibody was rapidly 
transduced into living β cells (unpublished data). We ensured 
that TAT-conjugated Cy3-labeled anti-Synt1A antibody specifi  -
cally labeled endogenous Synt1A clusters in the plasma mem-
brane. Cells treated with TAT-conjugated Cy3 anti-Synt1A mAb 
for 50 min were fi  xed and immunostained with anti-Synt1A pAb. 
As shown in Fig. S1 (available at http://www.jcb.org/cgi/content/
full/jcb.200608132/DC1), there was overlapping of Synt1A clus-
ters labeled with TAT-conjugated Cy3 anti-Synt1A mAb (red) 
and those stained with anti-Synt1A pAb (green). In addition, it 
should be noted that most endogenous Synt1A was labeled with 
TAT antibody.
Pancreatic β cells that expressed insulin-GFP (Fig. S1, 
green) and were treated with TAT-conjugated Cy3 anti-Synt1A 
antibody (red) were stimulated by 22 mM glucose. Dual-color 
TIRF images were obtained every 300 ms (Fig. 1 A). Approxi-
mately 75% of insulin granule fusion during the fi  rst phase 
(<4 min after stimulation) involved previously docked rather 
Figure 1.  Dual-color TIRFM of dynamic interaction between docking and fusing GFP-tagged insulin granules and Cy3-labeled Synt1A clusters in glucose-
induced insulin release in control mouse 𝗃 cells. 2 d after β cells were infected with the vector expressing insulin-GFP (green), cells were treated with TAT-
conjugated Cy3-labeled anti-Synt1A antibody (red) for 50 min. Images were recorded for GFP-tagged insulin granules (green) and Cy3-labeled Synt1A 
clusters (red) simultaneously (300-ms intervals). (A) Sites of insulin granule fusion events during ﬁ  rst-phase release under 22 mM glucose stimulation (0–4 min 
after glucose stimulation). Solid boxes (1 × 1 μm) represent the sites of fusion events at Synt1A clusters. Dashed boxes indicate the sites of fusion events 
not at Synt1A clusters (Video 1, available at http://www.jcb.org/cgi/content/full/jcb.200608132/DC1). (B) Analysis of fusion events during ﬁ  rst-phase 
release (n = 5 cells). The fused granules are divided into two categories, fusion from previously docked granules (red) and newcomers (green). Previously 
docked granule indicates that the morphologically previously docked granule is fused with the plasma membrane. Newcomer indicates that the granule ap-
proaches from the inside (being absent before stimulation), reaches the plasma membrane, and quickly fuses. As previously reported (Ohara-Imaizumi 
et al., 2004b),  75% of insulin granule fusion during the ﬁ  rst phase was from previously docked granules, and the remaining was from newcomers. Most 
fusion from previously docked granules occurred at Synt1A clusters (78.1 ± 4.0% of all fusion from previously docked granules); fusion from newcomers 
occurred external to Synt1A clusters (85.0 ± 2.9% of all fusion from newcomers) during the ﬁ  rst phase. Data are mean ± SEM. (C) Sequential images 
(1 × 1 μm, 300-ms intervals; A, box indicated by arrow) of fusion from previously docked granules (green) at the Synt1A cluster (red) during the ﬁ  rst phase. 
(D) Sites of insulin granule fusion during second-phase insulin release (>5 min after glucose stimulation; Video 2). Solid and dashed boxes are as described 
above. (E) Analysis of fusion events during second-phase release, with fusion occurring mostly from newcomers (Ohara-Imaizumi et al., 2004b), and 
at sites distinct from Synt1A clusters (86.1 ± 1.2% of all fusion from newcomers; n = 5 cells). Data are mean ± SEM. (F) Sequential images (1 × 1 μm, 
300-ms intervals; D, box indicated by arrow) of fusion from newcomers (green) external to Synt1A clusters (red) during the second phase.TIRF IMAGING ANALYSIS OF SYNT1A
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than newcomer granules (Fig. 1 B). We observed that most 
fusion events involving previously docked granules occurred at 
the site of Synt1A clusters (Fig. 1, B and C), whereas fusion from 
newcomers occurred at sites distinct from the Synt1A clusters. 
There was no signifi  cant difference in the number of fusion 
events between control (see Fig. 3 B) and TAT-conjugated Cy3 
anti-Synt1A mAb–treated β cells (Fig. 1 A): the total number of 
fusion events from previously docked granules in wild-type 
(WT) versus TAT-treated cells was 18.2 ± 1.8 versus 14.9 ± 3.1 
in 0–4 min (P = NS; n > 5 cells), suggesting that the introduc-
tion of TAT-conjugated Cy3 anti-Synt1A mAb into β cells does 
not affect insulin exocytosis. These results suggest that fi  rst-
phase release heavily involves a Synt1A-based SNARE com-
plex, whereas second-phase release is chiefl  y independent of a 
Synt1A-based SNARE complex.
Morphometric analysis of insulin granules 
in Synt1A
−/− mice
If Synt1A is essential for docking and fusing insulin granules 
specifi  cally during the fi  rst phase, the deletion of Synt1A may 
cause reduction in fi  rst-phase but not second-phase insulin 
  release. To examine this hypothesis, we used β cells from 
Synt1A
−/− mice (Fujiwara et al., 2006) as a context for analyz-
ing docking and fusion of insulin granules by TIRFM. We fi  rst 
investigated Synt1A protein levels in Synt1A
−/− versus WT 
mouse pancreatic islets. Fig. S2 (available at http://www.jcb
.org/cgi/content/full/jcb.200608132/DC1) shows the lack of 
Synt1A protein expression in Synt1A
−/− islets. Expression of 
Synt1B was not observed in either Synt1A
−/− or WT islets, in 
accord with the report that Synt1B is expressed at very low 
levels in control β cells (Nagamatsu et al., 1996), although the 
brain abundantly expresses Synt1B (Bennett et al., 1992). We 
found no difference between WT and Synt1A
−/− islets in expres-
sion levels of other plasma membrane proteins, such as Synt3, 
Synt4, the other SNAREs, and related proteins SNAP-25, VAMP2, 
and Munc18. We then examined the pancreatic islets morpho-
logically (Fig. S3). We found that paraffi  n-embedded pancreatic 
tissue sections showed insulin immunofl  uorescence patterns typi-
cal for β cells with no notable difference between the Synt1A
−/− 
and WT islets (Fig. S3, A and B). EM of pancreatic β cells also 
revealed that cell size, total number of granules per section, and 
mean granule diameter were similar between WT and Synt1A
−/− 
β cells (Fig. S3, C–F). Thus, Synt1A
−/− β cells displayed spe-
cifi  c Synt1A protein depletion but were similar to WT cells in 
these other traits assayed.
Docking status of insulin granules 
in Synt1A
−/− 𝗃 cells
We examined the docking status of insulin granules in Synt1A
−/− 
β cells using TIRFM with immunostaining for insulin (Fig. 2 A). 
Because evanescent fi  eld illumination reaches a <100-nm-thick 
layer immediately adjacent to the cover glass under our TIRF 
conditions, TIRFM illuminates only the plasma membrane with 
its associated organelles, such as synaptic vesicles (Zenisek et al., 
2000), secretory granules (Parsons et al., 1995), and glucose 
transporter 4 (GLUT4) vesicles (Lizunov et al., 2005), where a 
cell adheres tightly to the cover glass. We interpret the individual 
fl  uorescent spots shown in the TIRF image in Fig. 2 A to be 
equivalent to morphologically docked granules (see Materials 
and methods). We rarely observed morphologically docked gran-
ules in Synt1A
−/− β cells (number of docked granules: 253.3 ± 
10.2 vs. 12.3 ± 2.2 granules per 200 μm
2 in WT and Synt1A
−/− 
β cells, respectively; n = 12 cells; P < 0.0001). Plasma mem-
brane staining with a lipophilic dye ensured that the Synt1A
−/− 
β cells adhered tightly to the cover glass (unpublished data).
To confi  rm the TIRFM data, we used EM to examine in-
sulin granules that were morphologically docked to the plasma 
membrane. Using EM, granules at their shortest distance of 
<10 nm from the plasma membrane qualifi  ed as morphologi-
cally docked granules (Parsons et al., 1995; Fig. 2 B). The num-
ber of morphologically docked granules observed by EM was 
signifi  cantly reduced in Synt1A
−/− β cells (9.6 ± 1.5 vs. 0.8 ± 
0.2 granules per 10 μm of plasma membrane in WT and 
Synt1A
−/− cells, respectively; n = 12 cells; P < 0.0001). Along 
with the results of the morphometric analysis, these data suggest 
that Synt1A defi  ciency specifi  cally impairs the docking of insulin 
granules to the plasma membrane.
Figure 2.  Synt1A deﬁ  ciency impairs docking of insulin granules to the 
plasma membrane in pancreatic 𝗃 cells. (A) TIRFM of insulin granules morpho-
logically docked to the plasma membrane. (left) Typical TIRF images of 
docked insulin granules in WT or Synt1A
−/− β cells. The surrounding lines 
represent the outline of cells that attached to the cover glass. Bar, 5 μm. Pan-
creatic β cells were prepared from WT and Synt1A
−/− mice, ﬁ  xed, and 
immunostained for insulin. (right) Number of insulin granules morphologically 
docked to the plasma membrane. Individual ﬂ  uorescent spots shown in TIRF 
images were manually counted per 200 μm
2; n = 15 cells. (B) Electron 
  micrograph of β cell sections. (top) Typical EM images of the plasma mem-
brane area facing the blood capillary (C) of WT and Synt1A
−/− β cells (B). 
Bar, 500 nm. (bottom) Number of morphologically docked insulin granules 
per 10 μm of plasma membrane. Granules at their shortest distance of 
<10 nm from the plasma membrane were qualiﬁ  ed as morphologically docked 
granules (red arrowheads). Results are provided as the mean ± SEM.JCB • VOLUME 177 • NUMBER 4 • 2007  698
Effects of Synt1A ablation 
on insulin exocytosis
We explored the effects of Synt1A defi  ciency on the dynamic 
motion of single insulin granules. In agreement with what has 
been reported for rat β cells (Ohara-Imaizumi et al., 2004b), we 
found that in WT mouse β cells, fusion of insulin granules with 
the plasma membrane during fi  rst-phase release mainly involved 
previously docked granules (Fig. 3, A and B; and Video 3, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200608132/DC1). 
In contrast, because Synt1A
−/− β cells have fewer docked gran-
ules, TIRF analysis in these cells showed that the fusion from 
previously docked granules was severely abolished (Fig. 3, C 
and D; and Video 4). Despite an appreciable number of fusion 
events from previously docked granules in WT β cells, there 
was no fusion from previously docked granules in Synt1A
−/− 
β cells (18.2 ± 1.8 vs.0 in 0–4 min, WT vs. Synt1A
−/−; Fig. 3, 
B and D). However, some fusion from newcomer granules was 
observed during the fi  rst phase even in Synt1A
−/− β cells. During 
second-phase release (>4 min), there was no signifi  cant differ-
ence in the total number of newcomer fusion events between 
WT and Synt1A
−/− β cells (WT, 43.1 ± 5.0, and Synt1A
−/−, 
49.8 ± 3.7, during 4–17 min; P = NS; n = 10 cells; Fig. 3, 
B and D). ELISA data evaluating endogenous insulin release from 
perfused WT and Synt1A
−/− β cells (Fig. 3 E) were compat-
ible with the TIRFM data. The small peak of fi  rst-phase release 
from Synt1A
−/− β cells shown in perfusion analysis is inferred 
to be composed of fusion from newcomers. Both the amplitude 
and time course of the glucose-induced rise in intracellular Ca
2+ 
concentration ([Ca
2+]i) measured using Fura-2 were similar be-
tween WT and Synt1A
−/− β cells (Fig. 3 F), suggesting that glu-
cose metabolism and ATP production were normally processed 
in Synt1A
−/− β cells and that Synt1A does not affect the activity 
of the l-type Ca
2+ channels. This disagrees with the results of 
other groups (Yang et al., 1999; Kang et al., 2002; Lam et al., 
2005), but the reason for the discrepancy is unknown.
Restoration of Synt1A expression in 𝗃 cells 
of Synt1A
−/− mice
We performed rescue experiments to confi  rm Synt1A function 
in the docking and fusing of granules during fi  rst-phase release. 
Figure 3.  Effects of Synt1A deﬁ  ciency on glucose-induced biphasic insulin release. (A) TIRFM of single insulin granule motion in WT β cells under 22 mM 
high glucose stimulation (Video 3, available at http://www.jcb.org/cgi/content/full/jcb.200608132/DC1). Red and green boxes indicate that the gran-
ules to be fused with the plasma membrane originated from previously docked (red) or newcomer (green) granules. Sequential images (1 μm × 1 μm; 
300-ms intervals) of docking and fusion from the previously docked granules (red box) and the newcomers (green box) are presented. (B) Histogram of 
the number of fusion events (per 200 μm
2) in WT β cells at 60-s intervals after stimulation (n =10 cells). The red column shows fusion from previously 
docked granules, and the green column shows fusion from newcomers. During the ﬁ  rst phase, fusion occurred mostly from previously docked granules. 
The fusing granules during the second phase originated mostly from newcomers. (C) TIRFM during glucose stimulation in Synt1A
−/− β cells (Video 4) and 
sequential images of a newcomer granule docking and fusing (green box) under glucose stimulation. (D) Histogram of the number of fusion events (per 
200 μm
2) in the Synt1A
−/− cells at 60-s intervals after stimulation (n =10 cells). (E) Glucose-induced insulin release from perfused WT and Synt1A
−/− 
β cells stimulated with 22 mM glucose. The cells in the cell chamber ( 5 × 10
5 cells per chamber) were perfused with KRB (0.5 ml/min) at 37°C, and the 
perfusate was analyzed for insulin by ELISA. (F) 22 mM glucose-induced changes in [Ca
2+]i in WT and Synt1A
−/− β cells. Changes in [Ca
2+]i were mea-
sured by 2 μM Fura-2 AM. Time 0 indicates when the high glucose was added. The ﬂ  uorescence ratio (340/360) at time 0 was taken as 1. Results are 
provided as the mean ± SEM.TIRF IMAGING ANALYSIS OF SYNT1A
−/− MOUSE β CELLS • OHARA-IMAIZUMI ET AL. 699
We restored Synt1A protein expression to Synt1A
−/− β cells by 
infecting them with an adenovirus encoding Synt1A, Adex1CA 
Synt1A (Ax-Synt1A; Fig. 4 A). The number of Synt1A clusters 
was considerably restored, although to still subnormal levels 
(270.8 ± 13.0 vs. 212.4 ± 15.7, WT vs. Ax-Synt1A–infected 
Synt1A
−/− cells; P < 0.05). In accordance with restored Synt1A 
cluster levels, the number of docked insulin granules in Ax-
Synt1A–infected Synt1A
−/− cells was restored (261.1 ± 13.6 
vs. 230.0 ± 12.0, WT vs. Ax-Synt1A–infected Synt1A
−/− cells; 
P = NS). Infection of Adex1CA Synt1A did not alter the num-
ber of SNAP25 clusters (Fig. 4 B) that interact with Synt1 clus-
ters (Lang et al., 2002). We then performed TIRFM analysis of 
Figure 4.  Rescue of the number of docked insulin granules and fusion events by restoring Synt1A clusters to normal levels in Synt1A
−/− 𝗃 cells. (A–C) TIRF 
images and the quantitation of Synt1A clusters (A), SNAP-25 clusters (B), and docked insulin granules (C) on the plasma membrane in WT or Synt1A
−/− 
β cells. Synt1A
−/− cells were infected with empty virus Adex1w (Ax-Cont) or with Adex1CA Synt1A (Ax-Synt1A). Cells were ﬁ  xed and immunostained for 
Synt1A (A), SNAP-25 (B), and insulin (C). (top) Typical TIRF images. Surrounding lines represent the outline of cells attached to the cover glass. Bars, 5 μm. 
(bottom) Number of Synt1A (A) and SNAP-25 (B) clusters and docked insulin granules (C) on the plasma membrane. Individual ﬂ  uorescent spots in TIRF im-
ages were manually counted per 200 μm
2. Data are mean ± SEM (*, P < 0.05; **, P < 0.0001; n = 15 cells). (D) Rescue of fusion events in Synt1A
−/− 
β cells. Synt1A
−/− cells were infected with Adex1CA insulin GFP and then Ax-Cont or Ax-Synt1A. The histogram shows the number of fusion events (per 
200 μm
2) at 60-s intervals after high glucose stimulation. A marked increase in fusion events from previously docked granules was observed in the 
Synt1A
−/− cells infected with Ax-Synt1A relative to Ax-Cont–infected cells. (E) Dual-color TIRFM of docking and fusing GFP-tagged insulin granules (green) 
and Synt1A clusters labeled with TAT-conjugated Cy3-labeled anti-Synt1A antibody (red) in glucose-induced release from Ax-Synt1A–infected Synt1A
−/− 
cells. Most fusion from previously docked granules occurred at Synt1A clusters (76% of all fusion from previously docked granules); fusion from newcomers 
occurred external to Synt1A clusters (81% of all fusion from newcomers) during the ﬁ  rst phase. Data are mean ± SEM (n = 5 cells). Solid boxes (1 μm × 
1 μm) represent the sites of fusion events at the Synt1A clusters. Dashed boxes indicate the sites of fusion events external to the Synt1A clusters. (F) Sites of 
insulin granule fusion during second-phase insulin release (>4 min after glucose stimulation). Fusion events during second-phase release occurred mostly 
from newcomers and at sites distinct from Synt1A clusters (82% of all fusion from newcomers; n = 5 cells). Data are mean ± SEM. Solid and dashed boxes 
are as described above.JCB • VOLUME 177 • NUMBER 4 • 2007  700
the docking and fusion of insulin granules stimulated by 22 mM 
glucose in Ax-Synt1A–infected Synt1A
−/− β cells. This analy-
sis showed a substantial increase in fusion events from  previously 
docked granules (Fig. 4 D and Video 5, available at http://www
.jcb.org/cgi/content/full/jcb.200608132/DC1). The total number 
of fusion events from previously docked granules during the 
fi  rst phase in Ax-Synt1A–infected Synt1A
−/− β cells was restored 
(18.2 ± 1.8 vs. 12.7 ± 3.3 in 0–4 min, WT vs. Ax-Synt1A–
infected Synt1A
−/− cells; P = NS). Synt1A restoration did not 
affect fusion events from newcomers during the second phase. 
In addition, we examined the interaction between insulin gran-
ules and Synt1A clusters labeled with TAT-conjugated Cy3 
anti-Synt1A mAb in Ax-Synt1A–infected Synt1A
−/− cells. 
Dual-color TIRFM showed that previously docked granules fused 
at the site of the Synt1A clusters during the fi  rst phase; during 
the second phase, newcomer granules fused external to the 
Synt1A clusters (Fig. 4, E and F). This was also observed in WT 
β cells. These data support a model where Synt1A clusters are 
required for previously docked granules to dock and fuse during 
the fi  rst phase but dispensable for newcomers to dock and fuse 
during the second phase.
Other plasma membrane syntaxins assayed 
are not involved in second-phase release
As shown in Fig. 3 D, the fusion of newcomers during the sec-
ond phase was well preserved in the absence of Synt1A. Yet the 
question remained of whether other syntaxin isoforms might be 
functioning in second-phase release, as pancreatic β cells do 
express detectable levels of plasma membrane–localized syn-
taxin isoforms, such as Synt3 and -4 (Jacobsson et al., 1994; 
Wheeler et al., 1996). To investigate whether these membrane 
syntaxins Synt3 and -4 are involved in the second phase, we used 
TAT fusion proteins that encode the Synt3-H3 (TAT-Synt3-H3) 
and Synt4-H3 (TAT-Synt4-H3) domains. We previously  reported 
that the recombinant Synt1A SNARE motif (H3 domain) fused 
to TAT (TAT-Synt1A-H3) rapidly transduced into MIN6 β cells, 
inhibiting insulin release (Ohara-Imaizumi et al., 2002b). Because 
the syntaxin H3 domain contributes to one of the four α-helical 
bundles in the SNARE core complex (Jahn and Südhof, 1999), 
a large molar excess of the Synt1A-H3 domain fused to TAT 
  interrupted the formation of functional SNARE complexes 
(Ohara-Imaizumi et al., 2002b), as previously reported in other 
systems (Zhong et al., 1997; O’Connor et al., 1997). We therefore 
used TAT-H3 of each syntaxin isoform to perform dominant-
negative type experiments.
We fi rst produced TAT fusion proteins encoding the Synt3-
H3 (TAT-Synt3-H3) and Synt4-H3 (TAT-Synt4-H3) domains. 
In addition, we produced TAT fusion proteins that encoded the 
Synt1A-H3 (TAT-Synt1A-H3) and Synt1B-H3 (TAT-Synt1B-H3) 
domains. A non–coiled-coil domain of ELKS, which has no 
effect on insulin exocytosis, composed the peptide fusion in our 
TAT-Control (Ohara-Imaizumi et al., 2005). As shown in Fig. 5 
(C and D), the transduction of TAT-Synt3-H3 and TAT-Synt4-
H3 into WT β cells reduced the number of fusion events from 
Figure 5.  TIRFM of fusion of GFP-tagged 
  insulin granules in biphasic insulin release 
from WT 𝗃 cells treated with TAT-syntaxin-H3. 
WT cells expressing GFP-tagged insulin were 
treated with or without 70 mg/ml of TAT-Cont 
(A), TAT-Synt1A-H3 (B), TAT-Synt3-H3 (C), TAT-
Synt4-H3 (D), or TAT-Synt1B-H3 (E) fusion pro-
tein for 50 min, and TIRF images were acquired 
every 300 ms by 22 mM glucose stimulation. 
The histogram shows the number of fusion 
events (n = 10 cells each) at 1-min intervals 
after high glucose stimulation in the TAT fusion 
protein–treated cells. The red column shows 
the fusion from previously docked granules, 
and the green column shows fusion from new-
comers. Data are mean ± SEM.TIRF IMAGING ANALYSIS OF SYNT1A
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previously docked granules during the fi  rst phase to  58 and 
 59% that of control levels, respectively. Second-phase re-
lease, which consisted mostly of newcomers, was unaffected by 
the Synt3-H3 and Synt4-H3 constructs expressed. TAT-Control 
treatment had no effect on either phase (Fig. 5 A). However, 
TAT-Synt1A-H3 treatment strongly reduced the total number 
of fusion events from previously docked granules during the 
fi  rst phase to  23% that of control levels, while showing no 
effect on second-phase release (Fig. 5 B). These data are con-
sistent with our results from Synt1A
−/− β cells. Synt1B does 
not express in β cells, but TAT-Synt1B-H3 treatment showed 
results similar to those in the TAT-Synt1A-H3 treatment, reduc-
ing the total number of fusion events from previously docked 
granules during the fi  rst phase to  28% that of control levels 
(Fig. 5 E). This may be a refl  ection of a higher homology of 
Synt1B-H3 to Synt1A-H3. Overall, these fi  ndings suggest that 
these other syntaxin family members are not involved in second-
phase release.
Synt1A ablation results in impaired 
glucose tolerance
Because Synt1A
−/− β cells exhibit reduced fi  rst-phase insulin 
release, these mice would be expected to develop diabetes. The 
Goto-Kakizaki rat model for human type 2 diabetes is known 
to be defective in fi  rst-phase insulin release and displays hyper-
glycemia (Ostenson et al., 1993). In contrast, we found that 
Synt1A
−/− mice did not show any signifi  cant hyperglycemia; 
fasting blood glucose levels of Synt1A
−/− mice were not dif-
ferent from those of WT mice (Synt1A
−/−, 63.9 ± 4.3 mg/dl 
[n = 7], vs. WT, 65.1 ± 3.3 mg/dl [n = 11]; P = NS). However, 
the oral glucose tolerance test did show impaired glucose toler-
ance in Synt1A
−/− mice (Fig. 6 A). 30 min after challenge, blood 
glucose levels in Synt1A
−/− mice were signifi  cantly higher than 
in WT mice (Synt1A
−/−, 385.0 ± 14.1 mg/dl [n = 7], vs. WT, 
286.3 ± 10.4 mg/dl [n = 11]; P < 0.0001). In agreement with 
these data, we found serum insulin levels to be lower in Synt1A
−/− 
than in WT mice at 30 min after challenge (Fig. 6 B). Thus, 
Synt1A
−/− mice displayed an impaired glucose tolerance but 
not marked hyperglycemia.
Discussion
Our dual-color TIRFM approach has shown that during fi  rst- 
phase release insulin granules fuse at the site of Synt1A clus-
ters, but during second-phase release the granules fuse external 
to Synt1A clusters. We previously found that granules fusing 
during the fi  rst phase originated mostly from morphologically 
previously docked granules, whereas granules fusing during the 
second phase arose from newcomers that were originally stored 
intracellularly (Ohara-Imaizumi et al., 2004b). We also reported 
that previously docked insulin granules were colocalized with 
Synt1A clusters in the plasma membrane of MIN6 β cells 
(Ohara-Imaizumi et al., 2004a). Collectively, these fi  ndings 
suggested that Synt1A is probably essential for docking and 
fusing insulin granules during the fi  rst phase; however, no direct 
evidence existed to verify this. Recently, it was reported that 
other isoforms of the syntaxin family might be associated with 
biphasic insulin release (Saito et al., 2003; Spurlin and Thurmond, 
2006). We therefore used Synt1A
−/− mice to directly address 
how Synt1A functions in granule docking and fusing in biphasic 
insulin exocytosis.
First, we examined the docking status of insulin granules 
in Synt1A
−/− β cells. TIRFM and EM analysis in Synt1A
−/− 
β cells documented a marked reduction of the number of gran-
ules docked onto the plasma membrane. Because granules 
fused during the fi  rst phase originated from docked granules, as 
expected, TIRFM revealed that there was no fusion from 
docked granules during the fi  rst phase in knockout cells. How-
ever, fusion from newcomers was still preserved in Synt1A
−/− 
β cells under glucose stimulation. Consistent with these data, 
perfusion analysis of Synt1A
−/− β cells showed a marked re-
duction in fi  rst-phase insulin release but no change in second-
phase release. Furthermore, restoration of Synt1A to subnormal 
levels via the adenoviral vector in Synt1A
−/− β cells restored 
the insulin granules docked onto the plasma membrane, ac-
companied by an appreciable number of fusion events from 
these granules. Thus, our data provide direct evidence that 
Synt1A is essential for docking and fusion of insulin granules 
during fi  rst-phase release. The docking status of synaptic vesi-
cles in the brain hippocampus showed no difference between 
WT and Synt1A
−/− mice (Fujiwara et al., 2006). The reason for 
this discrepancy between brain and pancreatic β cells is un-
known, but it may be due to the expression of Synt1B, which is 
highly homologous to Synt1A and is abundant in brain cells 
(Bennett et al., 1992) but not in pancreatic β cells (Nagamatsu 
et al., 1996). Although the function of Synt1B may not be equal 
to that of Synt1A in pancreatic β cells (Nagamatsu et al., 1996), 
the brain may have either a tremendous safety network or a dif-
ferent system from pancreatic β cells that permits Synt1B or 
other homologues to compensate for the lack of Synt1A in 
brain tissue.
Although our data specify a requirement for Synt1A dur-
ing fi  rst-phase release, we still do not know whether other iso-
forms of the syntaxin family participate in the fi  rst phase. WT 
β cells transduced with TAT-Synt3-H3 and TAT-Synt4-H3, which 
function in a dominant-negative manner to the corresponding 
syntaxin isoforms, showed reduction to some extent in the 
  fusion events from previously docked granules during the fi  rst 
phase (Fig. 5). Yet, as no docked insulin granules were seen on 
Figure 6.  Glucose tolerance test in WT and Synt1A
−/− mice. (A) Oral glu-
cose tolerance was tested in WT (n = 11) and Synt1A
−/− (n = 7) mice. 
Blood glucose levels were measured at the indicated times after glucose 
challenge at 2 g glucose/kg body weight (n = 6 each; *, P < 0.005; 
**, P < 0.0001). (B) Plasma insulin levels were measured in WT and 
Synt1A
−/− mice during the oral glucose tolerance test at the indicated times. 
Results are provided as the mean ± SEM.JCB • VOLUME 177 • NUMBER 4 • 2007  702
the plasma membrane in Synt1A
−/− mice, it is diffi  cult to con-
clude that both Synt3 and -4 are associated with fi  rst-phase exo-
cytosis. Rather, we assume that the reduction of fusion events 
during the fi   rst phase by TAT-Synt3-H3 and TAT-Synt4-H3 
treatment may refl  ect the homology of their amino acid se-
quence to Synt1A-H3. Nevertheless, it remains to be empiri-
cally determined if, and how, the other plasma membrane 
syntaxins contribute to the fi  rst phase.
Fusion from newcomer granules was not altered at all re-
gardless of Synt1A deletion, indicating that this type of fusion 
may occur via some mechanism other than the Synt1A-based 
SNARE complex. Indeed, granule behavior between the fi  rst 
and second phases of release is quite different. As previously 
reported, upon reaching the plasma membrane, newcomers 
fused immediately (<50 ms), whereas granules previously 
docked on the plasma membrane stayed at the same place for a 
relatively long time (Ohara-Imaizumi et al., 2004b). To examine 
the possibility that other syntaxin isoforms are involved in 
 second-phase exocytosis, we performed dominant-negative type 
experiments with TAT-Synt3-H3 and TAT-Synt4-H3 and dem-
onstrated that there was no correlation between syntaxins and 
second-phase exocytosis. In agreement with our data, Spurlin 
and Thurmond (2006) noted only a slight decrease in second-
phase insulin release in Synt4
+/− mice. Thus, it is plausible that 
the fi  rst phase is Synt1A dependent but the second phase is 
Synt1A independent, as depicted in the Fig. 7. A similar pheno-
menon exists in neurotransmitter release, where neural t-SNARE 
SNAP-25 is essential for evoked neurotransmitter release but 
nonessential for nonevoked release (Washbourne et al., 2002). 
Furthermore, fusion via neural v-SNARE VAMP2 in evoked 
neurotransmitter release differs from spontaneous neurotrans-
mitter release (Schoch et al., 2001). Of course, we do not know 
whether an evoked or spontaneous release in neurons is com-
patible with the fi  rst and second phases of insulin release in 
pancreatic β cells, respectively, but there must be some  unknown 
mechanism (other than the SNARE-mediated docking and fu-
sion reactions) in different cell types. Further studies will be 
  required to identify the specifi  c molecules involved in new-
comer fusion.
In the present study, we also examined the in vivo effect of 
Synt1A ablation followed by reduced fi  rst-phase insulin release 
on glucose homeostasis. The lack of fi  rst-phase insulin release 
is a main manifestation of type 2 diabetes (Ward et al., 1984; 
O’Rahilly et al., 1986; Cerasi, 1994). This phenomenon is quite 
similar to the insulin release pattern observed in the perfusion of 
Synt1A
−/− β cells. Therefore, we expected Synt1A
−/− mice to 
become diabetic. The in vivo studies showed that Synt1A
−/− 
mice had impaired oral glucose tolerance and decreased serum 
insulin levels; however, there was no marked hyperglycemia. 
Thus, factors other than Synt1A depletion may be required to 
drive hyperglycemia. Williams-Beuren syndrome (Morris et al., 
1988) is an interesting clinical case when considering the role 
of Synt1A in diabetes pathogenesis. This syndrome is a multi-
system developmental disorder caused by the hemizygous dele-
tion of a 1.5-million-bp region of chromosome 7q11.23 (Ewart 
et al., 1993), which includes the Synt1A gene (Osborne et al., 
1997). Only some Williams-Beuren syndrome patients exhibit 
impaired glucose tolerance (Cherniske et al., 2004). This may 
be due to the hemizygous deletion; however, it is also postulated 
that deletion of only Synt1A is not enough to cause abnormal 
glucose homeostasis.
In summary, the present study has provided the fi  rst docu-
mentation that fi  rst-phase insulin release is Synt1A dependent, 
but second-phase release is Synt1A independent, highlighting 
that the two phases differ not only spatially but also mechanisti-
cally. In a physiological context, our data supporting glucose 
intolerance in Synt1A
−/− mice in vivo encourage therapeutic 
consideration of the signifi  cance of Synt1A in fi  rst-phase insu-
lin release.
Materials and methods
Generation of Synt1A
−/− mice
We generated Synt1A
−/− mice as previously described (Fujiwara et al., 
2006). The genotyping of mice was performed by PCR. Mice were back-
crossed with strain C57BL/6 over at least ﬁ  ve generations and were used 
at the age of 10–14 wk. Animal experiments were approved by the Kyorin 
University Animal Care Committee.
Cells
Pancreatic islets of Langerhans were isolated from male WT and Synt1A
−/− 
mice by collagenase digestion as described previously (Ohara-Imaizumi 
et al., 2004b). Isolated islets were dispersed in calcium-free Krebs-Ringer 
buffer (KRB) containing 1 mM EGTA and cultured on ﬁ  bronectin-coated 
(KOKEN Co.), high refractive index cover glass (Olympus) in RPMI 1640 
medium (Invitrogen) supplemented with 10% FBS (Invitrogen), 200 U/ml 
penicillin, and 200 μg/ml streptomycin at 37°C in an atmosphere of 5% 
CO2. To label the insulin secretory granules, pancreatic β cells were in-
fected with recombinant adenovirus Adex1CA insulin-GFP as described 
previously (Ohara-Imaizumi et al., 2004b). For Synt1A rescue experi-
ments, cells were infected with Adex1CA Synt1A (Nagamatsu et al., 
1999) before being infected with Adex1CA insulin-GFP. Experiments were 
performed 2 d after the ﬁ  nal infection.
Immunoblotting
Proteins were extracted from mouse whole brain or mouse pancreatic islets 
and immunoblotted as previously described (Ohara-Imaizumi et al., 2005). 
Anti-Synt1A mAb and anti-Synt1B pAb were obtained also as previously 
Figure 7.  Schematic drawing of the role of Synt1A in biphasic insulin release. 
During ﬁ  rst-phase insulin release, granules dock to Synt1A clusters and fuse 
at the site of Synt1A clusters. During second-phase release, granules move 
to the plasma membrane from the intracellular store and then fuse with the 
plasma membrane without any interaction with Synt1A clusters.TIRF IMAGING ANALYSIS OF SYNT1A
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described (Fujiwara et al., 2006). Antibodies against Synt3 (Synaptic Sys-
tems GmbH), Synt4 (BD Biosciences), SNAP-25 (Wako), VAMP2 (Wako), 
and Munc18 (BD Biosciences) were purchased from commercial sources.
Immunostaining
WT and Synt1A
−/− β cells cultured on high refractive index glass were 
ﬁ  xed and made permeable with 2% paraformaldehyde/0.1% Triton X-100 
and were processed for immunohistochemistry as described previously 
(Ohara-Imaizumi et al., 2004b). Cells were labeled with anti-insulin mAb 
(Sigma-Aldrich), Synt1A, and SNAP-25 and processed with goat anti–
mouse IgG conjugated to Alexa Fluor 488 (Invitrogen; Ohara-Imaizumi 
et al., 2004b). Immunoﬂ  uorescence was detected by TIRFM. This procedure 
allowed us to evaluate the number of docked insulin granules and clusters 
of Synt1A and SNAP-25.
EM
EM was performed by conventional methods as previously described 
  (Akimoto et al., 1999). Tissues were ﬁ  xed in phosphate-buffered 2.5% glu-
taraldehyde, pH 7.4, postosmicated, dehydrated with graded alcohols, 
and embedded in Epon 812. After staining with uranyl acetate and lead 
citrate, ultrathin sections were examined with a transmission electron micro-
scope (TEM-1010C; JEOL). In EM, granules at their shortest distance of 
<10 nm from the plasma membrane were qualiﬁ  ed as morphologically 
docked granules (Parsons et al., 1995).
Morphometric analysis of islets
For the analysis of islet size and β cell mass, parafﬁ  n-embedded pancreas 
sections (10 μm) were labeled with anti-insulin antibody and detected by 
an avidin-biotin-peroxidase technique (Vector Laboratories). Sections were 
collected at 500-μm intervals from tissue blocks, and all islets in the sec-
tions were analyzed as islet area over total pancreatic area. Images were 
acquired with a microscope (IX70; Olympus) that was equipped with a 
charge-coupled device (CCD) camera and analyzed with MetaMorph soft-
ware (Universal Imaging Corp.).
TAT-conjugated antibody
TAT-conjugated Cy3-labeled anti-Synt1A antibody was prepared as de-
scribed elsewhere (Ohara-Imaizumi et al., 2004a). In brief, anti-Synt1A 
mAb was labeled with Cy3 by use of a Fluoro Link antibody Cy3 labeling 
kit (GE Healthcare), according to the manufacturer’s instructions. The Cy3-
labeled antibody was dialyzed against 0.1 M borate buffer and was incu-
bated with a ﬁ   vefold molar excess of a cross-linker, sulfosuccinimidyl 
6-(3′-[2-pyridyldithio]-propionamido) hexanoate (Pierce Chemical Co.) for 
3 h at room temperature. The conjugated antibody was separated from the 
free cross-linker by gel ﬁ  ltration eluted with 5 mM Hanks’ Hepes buffer, 
pH 7.2. A 10-fold molar excess of TAT protein transduction domain (PTD) 
peptide (G  Y  G  R  K  K  R  R  Q  R  R  R  G  G  G  C  ) was added to the conjugated antibody, 
and the mixture was incubated overnight at 4°C. The TAT-conjugated anti-
body was separated from the free TAT PTD peptide by gel ﬁ  ltration eluted 
with 5 mM Hanks’ Hepes buffer. On the day of TIRFM experiments, 
Adex1CA insulin-GFP–infected cells were treated with  120 μg/ml TAT-
conjugated Cy3-labeled anti-Synt1A mAb for 50 min as described previ-
ously (Ohara-Imaizumi et al., 2004a).
TAT fusion proteins
To produce constructs in which the TAT PTD peptide is located at the N ter-
minus of Synt1A-H3 (aa 202–265), Synt1B-H3 (aa 201–264), Synt3-H3 
(aa 201–264), Synt4-H3 (aa 210–273), or control peptides (non–coiled-
coil domain of ELKS; aa 324–403; Ohara-Imaizumi et al., 2005), the cod-
ing region that corresponds to rat Synt1A-H3, Synt1B-H3, Synt3-H3, 
Synt4-H3, or control peptides was ampliﬁ  ed by PCR by using oligonucleo-
tide primers, including the nucleotide sequence against the TAT PTD pep-
tide (Y  G  R  K  K  R  R  Q  R  R  R  ) in each sense primer, as described previously 
(Ohara-Imaizumi et al., 2002b). PCR products were subcloned into a 
pPROEX HTa bacterial expression vector (Invitrogen) with an additional 
His6 tag at the N terminus. The resulting products were conﬁ  rmed by an 
automated DNA sequencer (GE Healthcare). TAT fusion proteins in the 
pPROEX HTa vector were expressed in a DH5α Escherichia coli strain by 
induction with isopropyl-b-D-thiogalactopyranoside for 5 h at 37°C. The 
  recombinant proteins were extracted with 8 M urea in 50 mM Tris and 
100 mM KCl, pH 8.0. Urea extracts were incubated with Ni-NTA-agarose 
(QIAGEN) before washing, and stepwise removal of urea was performed 
to allow renaturation of bound protein. Proteins were eluted from Ni-agarose 
by 200 mM imidazole and were desalted on a PD-10 column (GE Health-
care) with Hanks’ balanced salt solution (Invitrogen).
TIRFM
The Olympus total internal reﬂ  ection system was used with a high-aperture 
objective lens (Apo 100× OHR; NA 1.65; Olympus) as previously pub-
lished (Ohara-Imaizumi et al., 2002a). To observe GFP or Alexa Fluor 488 
alone, we used a 488-nm laser line for excitation and a 515-nm long-pass 
ﬁ  lter for the barrier. Diiodomethane sulfur immersion oil (n = 1.81; Car-
gille Laboratories) was used to make contact between the objective lens 
and the high refractive index cover glass. Light propagates through the 
cover glass at an angle measured as 65° and undergoes total internal re-
ﬂ  ection at the glass–cell interface. The refractive indices for glass (n = 1.8 
at 488 nm) and cells (n = 1.37) predict an evanescent ﬁ  eld declining 
e-fold within 44 nm from the interface and to  10% within 100 nm. A gran-
ule 100 nm from the interface would be illuminated too dimly to be visible 
under our conditions. Thus, we look barely 100 nm into the cell, a distance 
comparable to the thickness of ultrathin sections cut for EM (Zenisek et al., 
2000). In an evanescent ﬁ  eld declining e-fold within 44 nm, a granule at 
80% brightness would have a vertical distance of 9.6 nm from the plasma 
membrane and qualify as a morphologically docked granule (granule dis-
tance from plasma membrane <10 nm in EM studies; Parsons et al., 
1995). Images were projected onto a CCD camera (DV887DCSBV; 
Andor) operated with MetaMorph version 6.3. Images were acquired at 
300-ms intervals. For real-time images of GFP-tagged insulin granule mo-
tion by TIRFM, treated β cells were placed on the high refractive index 
glass, mounted in an open chamber, and incubated for 30 min at 37°C in 
KRB containing 110 mM NaCl, 4.4 mM KCl, 1.45 mM KH2PO4, 1.2 mM 
MgSO4, 2.3 mM calcium gluconate, 4.8 mM NaHCO3, 2.2 mM glucose, 
10 mM Hepes, pH 7.4, and 0.3% bovine serum albumin. Cells were then 
transferred to the thermostat-controlled stage (37°C) of TIRFM, and stimula-
tion with glucose was achieved by the addition of 52 mM glucose-KRB into 
the chamber for a ﬁ  nal concentration of 22 mM glucose. Most analyses, 
including tracking (single projection of different images) and area calcula-
tions were performed using MetaMorph software. To analyze the data, fu-
sion events were manually selected, and the mean ﬂ  uorescence intensity of 
individual granules in a 1 μm × 1 μm square placed over the granule cen-
ter was calculated. The number of fusion events was manually counted 
while looping  5,000 frame time lapses. To observe the ﬂ  uorescence of 
GFP and Cy3 simultaneously, we used the 488-nm laser line for excitation 
and an image splitter (Optical Insight) that divided the green and red com-
ponents of the images with a 565-nm dichroic mirror (Q565; Chroma 
Technology Corp.), passing the green component through a 530 ± 15 nm 
bandpass ﬁ  lter (HQ530/30 m; Chroma Technology Corp.) and the red 
component through a 630 nm ± 25 nm bandpass ﬁ  lter (HQ630/50 m 
[Chroma Technology Corp.]; Ohara-Imaizumi et al., 2005). Images were 
then projected side by side onto a CCD camera. The two images were 
brought into focus in the same plane by adding weak lenses to one chan-
nel, and they were brought into register by careful adjustment of the mirrors 
in the image splitter. Before each experimental session, we took an align-
ment image that showed density by means of scattered 90 nm TetraSpeck 
ﬂ  uorescent beads (Invitrogen). They were visible in both the green and red 
channels, and thus provided markers in the x-y plane. Beads in the two im-
ages were brought into superposition by shifting one image using Meta-
Morph software.
Insulin release assay
β cells were housed in a small chamber ( 5 × 10
5 cells/chamber) and 
perfused with KRB (2.2 mM glucose) for 60 min at a ﬂ  ow rate of 0.5 ml/min 
at 37°C before collecting fractions. Insulin release was stimulated by 22 mM 
glucose. Fractions were collected at 1-min intervals. Insulin release in 
aliquots of media was measured by an insulin ELISA kit (Morinaga).
Measurement of [Ca
2+]i
β cells were loaded with 2 μM fura-2 acetoxymethyl ester (Fura-2 AM; 
  Invitrogen) for 30 min at 37°C in KRB (2.2 mM glucose) and washed and 
incubated for an additional 15 min with KRB. Coverslips were mounted on 
an ARGUS/HiSCA system (Hamamatsu Photonics). Fura-2 ﬂ  uorescence 
was detected by the cooled CCD camera after excitation at 340 nm (F340) 
and 380 nm (F380), and the ratio image (F340/F380) was calculated 
with the ARGUS/HiSCA system.
Oral glucose tolerance test
Male mice age 10–14 wk were fasted for 14–15 h before the test. Glucose 
was administered orally at 2 g glucose/kg body weight. Blood samples 
were collected from a tail vein at 0, 30, 60, 90, and 120 min after 
  loading. Blood glucose levels were measured by Glutest R (Sanwa Kagaku 
Kenkyusyo). Plasma insulin levels were measured by an insulin ELISA kit.JCB • VOLUME 177 • NUMBER 4 • 2007  704
Online supplemental material
Fig. S1 shows a TIRF image of Synt1A clusters in the plasma membrane 
  labeled with TAT-conjugated Cy3-labeled anti-Synt1A mAb and stained 
with anti-Synt1A pAb. Fig. S2 shows an immunoblot analysis of Synt1A 
and other SNARE proteins in the brain and pancreatic islets from WT and 
Synt1A
−/− mice. Fig. S3 shows microscopic examination of pancreatic 
  islets in WT and Synt1A
−/− mice. Video 1 displays dual-color TIRF images 
of GFP-tagged insulin granules and Cy3-labeled Synt1A clusters during 
ﬁ   rst-phase insulin release (0–4 min after glucose stimulation). Video 2 
shows dual-color TIRFM of GFP-tagged insulin granules and Cy3-labeled 
Synt1A clusters during second-phase insulin release (>4 min after glucose 
stimulation). Video 3 shows TIRFM of GFP-tagged insulin granule motion in 
the WT mouse β cell under 22 mM glucose stimulation. Video 4 shows 
TIRFM of GFP-tagged insulin granule motion in the Synt1A
−/− mouse β cell 
under 22 mM glucose stimulation. Video 5 shows TIRFM of GFP-tagged in-
sulin granule motion in the Synt1A
−/− mouse β cell infected with Ax-Synt1A 
under 22 mM glucose stimulation. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200608132/DC1.
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